PIKfyve Inhibitors
PIKfyve (Phosphoinositide Kinase, FYVE-type zinc finger containing) is a large, multidomain phosphoinositide kinase that plays a central role in endosomal trafficking and lysosomal function. It is the primary enzyme responsible for synthesizing phosphatidylinositol 3,5-bisphosphate [PI(3,5)P2] from phosphatidylinositol 3-phosphate (PI3P) and, to a lesser extent, phosphatidylinositol 5-phosphate (PI5P). PIKfyve functions as part of a ternary complex known as the PAS complex, which also includes the scaffold protein VAC14 and the phosphoinositide phosphatase FIG4. This complex regulates the levels of PI(3,5)P2, which in turn controls the recruitment of various effector proteins involved in endosome maturation, vacuole acidification, and the recycling of membrane proteins. Inhibition of PIKfyve has profound effects on the endolysosomal system, typically resulting in the formation of large, swollen cytoplasmic vacuoles. This unique phenotype has been exploited for several therapeutic applications.
One of the most prominent is in the field of virology; PIKfyve is required for the entry and trafficking of several enveloped viruses, including SARS-CoV-2, Ebola, and Marburg virus. By blocking PIKfyve, viral particles are trapped within late endosomes, preventing their release into the cytosol. Additionally, PIKfyve inhibitors are being investigated for cancer therapy, as they can disrupt the autophagic flux and lysosomal degradation that many tumors rely on for survival. There is also emerging interest in using these inhibitors for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), where modulating the endolysosomal pathway might help clear protein aggregates. The most well-known and widely used PIKfyve inhibitor is apilimod (formerly STA-5326). Originally developed as an IL-12/IL-23 inhibitor for the treatment of autoimmune diseases like Crohn's disease and rheumatoid arthritis, it was later discovered that its primary molecular target is PIKfyve.
While it did not show sufficient efficacy in autoimmune trials, it has been repurposed for oncology and infectious disease research. Other inhibitors include YM201636 and the more recently developed WX8. Apilimod remains the most potent and selective tool available, with a high affinity for the ATP-binding site of PIKfyve. Classifications of PIKfyve inhibitors are currently limited, as most compounds are small-molecule ATP-competitive inhibitors. The field is focused on improving the pharmacokinetic properties and reducing the potential for off-target effects. A major challenge with PIKfyve inhibition is the dramatic vacuolization it induces in almost all cell types, which raises concerns about long-term toxicity and its impact on normal tissue homeostasis.
However, clinical data from apilimod trials suggest that the drug is relatively well-tolerated at doses that achieve significant target engagement. Future research aims to better understand the downstream effectors of PI(3,5)P2 and to determine whether targeting specific components of the PAS complex might offer a more nuanced way to modulate this pathway.
